

PRODUCT END OF SERVICE NOTICE For Selenia® Mammography System

April 2024

Dear Customer:

Our ambition to be the leading manufacturer of Women's Health products is a goal that cannot be achieved without you. To achieve this, we are dedicated to delivering the highest quality service, product support and technologically advanced products.

Our Selenia® mammography system has been end of life since September, 2022, with the commitment to provide service on a "Time & Material" basis when available. Due to resource and supply constraints, we will no longer provide service for these systems after December 31, 2024. Replacement parts and onsite support will not be available. Phone support following this date will be limited and cannot be guaranteed due to the age of the product and the need to support our active product lines.

We will continue to honor any remaining service contracts in place after December 31, 2024 to the best of our ability dependent on the availability of service parts. Additionally, no renewals or extensions will be available.

We encourage you to contact your local Hologic representative, for information about alternative products including our 3Dimensions™ mammography system. The 3Dimensions™ mammography system is used to perform the Genius® 3D Mammography exam, which is more accurate than conventional 2D mammograms, detecting 20%-65% more invasive breast cancers.¹⁻⁸

For more information, please visit Hologic.com/Breast-Health.

We at Hologic look forward to continuing to partner with you to serve you and your patients. We remain committed to providing the highest-quality products and service.

Sincerely,

Lisa Rudnick

Sr. Director, Global Services Commercial



References

- 1. FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005
- **2.** Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
- **3.** Zuckerman SP, Conant EF, Keller BM, et al. Implementation of Synthesized Two-dimensional Mammography in a Population-based Digital Breast Tomosynthesis Screening Program. Radiology. 2016 Dec; 281(3):730-736.
- **4.** Skaane P, Bandos A, Eben EB, et al. Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology. 2014 Jun; 271(3):655-63.
- **5.** Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
- **6.** McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737 43.
- 7. Rafferty EA, Durand MA, Conant EF, et al. Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6.
- 8. Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00019 Rev 003 (2017)